NUMAR Corporation was established to develop a downhole tool to measure certain geological properties (NMR) related to the evaluation of the productivity of oil and gas in shaly reservoirs.

Encore Wire was established to manufacture copper electrical building wire using a mini-mill concept. The company went public in 1993 and is located in McKinney, Texas.

Photometrics was established to manufacture extremely high-resolution scientific grade cameras in a plethora of industries.

Metal Oxide Technologies was established to be the first commercial manufacturer of high temperature superconducting wire from technology developed at the University of Houston. Significant progress has been made. The wire currently manufactured in the pilot line is of very high quality, and Metox’s patented process allows for extremely low cost in a full commercial setting. 

A state-of-the-art manufacturing facility was built in Houston on Tanner Road in 2023. Primary partners include Koch Industries. While initial commercial sales have not been achieved, Metox believes it will be the largest, most advanced manufacturer of high temperature superconductor wire in the world.

Superconductive wire is a key component for Fusion Energy, which will herald the next energy revolution.

Diakonos Oncology is a Houston- based biotech developing a first-in-class dendritic cell therapy originally
discovered at MD Anderson and Baylor College of Medicine. Diakonos’ approach has significant patent
protection and represents a new approach to immunotherapy.

Diakonos has raised $31.4 million over the past two years, including investment from Baylor College of
Medicine and the Brain Tumor Investment Fund, giving the company runway into late-2026. The company
is now opening a $35M round to extend its runway through the end of 2028, which would provide funding
to complete ongoing clinical trials and enable potential FDA drug approval submissions.

Finally, Diakonos’ platform has the power to treat a variety of cancers and truly has platform technology
potential. The company has seen it work across multiple cancer types both in the clinic and preclinically,
and this positions Diakonos as one of the few companies with a chance to transform outcomes in some of
the most challenging cancers.

This is a revolutionary immunological treatment for cancer. FDA approval is anticipated in early 2028.